StockNews.com Initiates Coverage on Aspira Women’s Health (NASDAQ:AWH)

Stock analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners cut their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 9.9 %

Shares of Aspira Women’s Health stock opened at $0.89 on Friday. The company has a market capitalization of $14.84 million, a price-to-earnings ratio of -0.74 and a beta of 1.44. The stock’s 50-day simple moving average is $0.84 and its 200-day simple moving average is $1.26. Aspira Women’s Health has a 52 week low of $0.67 and a 52 week high of $5.65.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health at the end of the most recent reporting period. 12.19% of the stock is currently owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.